Expanding on the success of cell therapy in hematological malignancies, investors put $300 million in 2022 toward cell therapies that can tackle the effects of complex degenerative conditions such as chronic liver and kidney diseases.
Regenerative medicines. Expanding on the success of cell therapy in hematological malignancies, investors put $300 million in 2022 toward cell therapies that can tackle the effects of complex degenerative conditions such as chronic liver and kidney diseases. Start-ups are developing engineered macrophages and regulatory T cells that may reverse the immune drivers of disease. Others are hoping to reverse fibrotic damage and promote new tissue growth in damaged organs using reprogrammed stem cells.